Fennec Pharmaceuticals Inc (FENC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fennec Pharmaceuticals Inc (FENC) has a cash flow conversion efficiency ratio of 0.001x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($50.00K) by net assets ($42.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see FENC company net worth for the company's overall valuation and market capitalisation.
Fennec Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Fennec Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Fennec Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fennec Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Fennec Pharmaceuticals Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Simulations Plus Inc
NASDAQ:SLP
|
0.074x |
|
Beijing AriTime Intelligent Control Co Ltd
SHG:600560
|
-0.046x |
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
-0.006x |
|
Berjaya Corporation Bhd
KLSE:3395
|
-0.049x |
|
Viva Wine Group AB
ST:VIVA
|
0.014x |
|
Guangdong Failong Crystal Technology Co Ltd
SHE:300460
|
0.028x |
|
Fonciere Inea
PA:INEA
|
0.034x |
|
Aurora Corp
TW:2373
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Fennec Pharmaceuticals Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Fennec Pharmaceuticals Inc from 1999 to 2025. View today's stock price for Fennec Pharmaceuticals Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $35.05 Million | $-12.47 Million | -0.356x | +92.26% |
| 2024-12-31 | $-5.87 Million | $26.98 Million | -4.595x | -411.49% |
| 2023-12-31 | $-11.62 Million | $-17.14 Million | 1.475x | -79.02% |
| 2022-12-31 | $-2.57 Million | $-18.06 Million | 7.029x | +879.53% |
| 2021-12-31 | $15.77 Million | $-14.22 Million | -0.902x | -68.09% |
| 2020-12-31 | $29.07 Million | $-15.60 Million | -0.536x | +29.69% |
| 2019-12-31 | $11.88 Million | $-9.06 Million | -0.763x | -107.78% |
| 2018-12-31 | $21.31 Million | $-7.83 Million | -0.367x | -169.84% |
| 2017-12-31 | $26.76 Million | $-3.64 Million | -0.136x | +77.13% |
| 2016-12-31 | $3.57 Million | $-2.12 Million | -0.595x | +82.49% |
| 2015-12-31 | $548.00K | $-1.86 Million | -3.398x | -22.59% |
| 2014-12-31 | $613.00K | $-1.70 Million | -2.772x | -282.48% |
| 2013-12-31 | $-1.46 Million | $-2.21 Million | 1.519x | +151.48% |
| 2012-12-31 | $-4.96 Million | $-2.99 Million | 0.604x | -97.75% |
| 2011-12-31 | $-120.00K | $-3.23 Million | 26.883x | +6765.85% |
| 2010-12-31 | $-4.92 Million | $-1.93 Million | 0.392x | +103.39% |
| 2009-12-31 | $406.00K | $-4.69 Million | -11.547x | -226.17% |
| 2008-12-31 | $3.05 Million | $-10.81 Million | -3.540x | -276.50% |
| 2007-12-31 | $14.15 Million | $-13.30 Million | -0.940x | +47.07% |
| 2006-12-31 | $7.58 Million | $-13.47 Million | -1.777x | -190.61% |
| 2005-12-31 | $20.06 Million | $-12.26 Million | -0.611x | -236.82% |
| 2003-12-31 | $33.00 Million | $-5.99 Million | -0.181x | +48.85% |
| 2002-12-31 | $15.31 Million | $-5.43 Million | -0.355x | +33.18% |
| 2001-12-31 | $6.08 Million | $-3.23 Million | -0.531x | -93.96% |
| 2000-12-31 | $9.82 Million | $-2.69 Million | -0.274x | +98.95% |
| 1999-12-31 | $46.73K | $-1.22 Million | -26.189x | -- |
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has co… Read more